165 related articles for article (PubMed ID: 37129184)
41. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.
Sastre J; Grávalos C; Rivera F; Massuti B; Valladares-Ayerbes M; Marcuello E; Manzano JL; Benavides M; Hidalgo M; Díaz-Rubio E; Aranda E
Oncologist; 2012; 17(3):339-45. PubMed ID: 22363067
[TBL] [Abstract][Full Text] [Related]
42. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B
Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035
[TBL] [Abstract][Full Text] [Related]
43. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
[TBL] [Abstract][Full Text] [Related]
44. Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip.
Huang MY; Liu HC; Yen LC; Chang JY; Huang JJ; Wang JY; Lin SR
Tumour Biol; 2014 Oct; 35(10):9639-47. PubMed ID: 24964961
[TBL] [Abstract][Full Text] [Related]
45. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Ku GY; Haaland BA; de Lima Lopes G
Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
[TBL] [Abstract][Full Text] [Related]
46. A meta analysis of cetuximab plus oxaliplatin based chemotherapy regimen for metastatic colorectal cancer.
Zhu YL; Lou J; Guo JY; Huang Z; Lv SW
Indian J Cancer; 2014 Mar; 51 Suppl 3():e113-6. PubMed ID: 25818736
[TBL] [Abstract][Full Text] [Related]
47. Cetuximab/irinotecan-chemotherapy in KRAS wild-type pretreated metastatic colorectal cancer: a pooled analysis and review of literature.
Barni S; Ghilardi M; Borgonovo K; Cabiddu M; Zaniboni A; Petrelli F
Rev Recent Clin Trials; 2013 Jun; 8(2):101-9. PubMed ID: 23859115
[TBL] [Abstract][Full Text] [Related]
48. Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
Wen F; Tang R; Sang Y; Li M; Hu Q; Du Z; Zhou Y; Zhang P; He X; Li Q
Cancer Sci; 2013 Oct; 104(10):1330-8. PubMed ID: 23822592
[TBL] [Abstract][Full Text] [Related]
49. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
50. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Shitara K; Yuki S; Yoshida M; Takahari D; Utsunomiya S; Yokota T; Sato Y; Inaba Y; Tajika M; Kawai H; Yamaura H; Kato M; Yamazaki K; Komatsu Y; Muro K
Invest New Drugs; 2012 Apr; 30(2):787-93. PubMed ID: 21174225
[TBL] [Abstract][Full Text] [Related]
52. A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer.
Makatsoris T; Kalofonos HP; Aravantinos G; Papadimitriou C; Kastritis E; Rigatos SK; Xiros N; Petsas T; Economopoulos T; Sakadamis AK; Fountzilas G;
Int J Gastrointest Cancer; 2005; 35(2):103-9. PubMed ID: 15879624
[TBL] [Abstract][Full Text] [Related]
53. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
Soeda H; Shimodaira H; Watanabe M; Suzuki T; Gamoh M; Mori T; Komine K; Iwama N; Kato S; Ishioka C
Int J Clin Oncol; 2013 Aug; 18(4):670-7. PubMed ID: 22638623
[TBL] [Abstract][Full Text] [Related]
54. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
Stintzing S; Fischer von Weikersthal L; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Giessen C; Moosmann N; Heinemann V
Br J Cancer; 2011 Jul; 105(2):206-11. PubMed ID: 21750558
[TBL] [Abstract][Full Text] [Related]
55. Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
Watts K; Wills C; Madi A; Palles C; Maughan TS; Kaplan R; Al-Tassan NA; Kerr R; Kerr D; Gray V; West H; Houlston RS; Escott-Price V; Cheadle JP
Int J Cancer; 2021 Nov; 149(9):1713-1722. PubMed ID: 34270794
[TBL] [Abstract][Full Text] [Related]
56. Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial.
Wang L; Liu Y; Yin X; Fang W; Xiong J; Zhao B; Zhang M; Zou Y; Qiu H; Yuan X
JAMA Netw Open; 2020 Jul; 3(7):e2011036. PubMed ID: 32687588
[TBL] [Abstract][Full Text] [Related]
57. Metastatic colorectal cancer: current systemic treatment options.
Board RE; Valle JW
Drugs; 2007; 67(13):1851-67. PubMed ID: 17722954
[TBL] [Abstract][Full Text] [Related]
58. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
[TBL] [Abstract][Full Text] [Related]
59. Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
Watts K; Wills C; Madi A; Palles C; Maughan TS; Kaplan R; Al-Tassan NA; Kerr R; Kerr DJ; Houlston RS; Escott-Price V; Cheadle JP
Int J Cancer; 2022 Sep; 151(6):957-966. PubMed ID: 35467766
[TBL] [Abstract][Full Text] [Related]
60. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Twelves CJ; Butts CA; Cassidy J; Conroy T; Braud Fd; Diaz-Rubio E; Tabernero JM; Schoffski P; Figer A; Brunet R; Grossmann J; Sobrero AF; Van Cutsem EJ
Clin Colorectal Cancer; 2005 Jul; 5(2):101-7. PubMed ID: 16098250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
